Intraoperative lymphatic mapping and sentinel lymph node dissection in breast cancer

Ca-A Cancer Journal for Clinicians

Volumn 50, Issue 5, 2000, Pages 279-291

  Hsueh, Eddy C ^a   Hansen, Nora ^b   Giuliano, Armando E ^a,b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Joyce Eisenberg Keefer Breast Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN TC 99M; ANESTHETIC AGENT; DEXTRAN TC 99M; DYE; ISOSULFAN BLUE; TECHNETIUM SULFUR COLLOID TC 99M; TRACER;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; GENERAL ANESTHESIA; HISTOPATHOLOGY; HUMAN; INJECTION SITE; INTERMETHOD COMPARISON; ISOTOPE LABELING; LOCAL ANESTHESIA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; LYMPHOSCINTIGRAPHY; MAMMOGRAPHY; MORBIDITY; PRIORITY JOURNAL; RADIOACTIVITY; SEDATION; SKIN INCISION; SURGICAL TECHNIQUE; TUMOR LOCALIZATION;

EID: 0033724654     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.50.5.279     Document Type: Article

References (68)

1. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases
2. Pathologic findings from the National Surgical Adjuvant Project for Breast Cancers (protocol no.4). X. Discriminants for tenth year treatment failure
3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
4. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
5. The new era in breast cancer: Invasion, size, and nodal involvement dramatically decreasing as a result of mammographic screening
6. NIH consensus conference. Treatment of early-stage breast cancer
7. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer
8. Regional nodal failure after conservative surgery and radiotherapy for early-stage breast carcinoma
9. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer
10. Assessment of morbidity from complete axillary dissection
11. Risk of lymphoedema following the treatment of breast cancer
12. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy
13. Arm morbidity following treatment of breast cancer with total axillary dissection: A multivariated approach
14. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. The Breast Carcinoma Collaborative Group of the Institut Curie
15. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast
16. Clinical and biological prediction of axillary and internal mammary lymph node metastases in breast cancer
17. Accuracy of ultrasound and clinical examination in the diagnosis of axillary lymph node metastases in breast cancer
18. Radical axillary dissection in the staging and treatment of breast cancer
19. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
20. Assessment of axillary lymph node status
21. Lymphatic mapping and sentinel lymphadenectomy for breast cancer
22. Technical details of intraoperative lymphatic mapping for early stage melanoma
23. The orderly progression of melanoma nodal metastases
24. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes
25. Sentinel lymphadenectomy in breast cancer
26. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer
27. Improved axillary staging of breast cancer with sentinel lymphadenectomy
28. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma
29. Sentinel lymphadenectomy for breast cancer in a community managed care setting
30. Axillary staging utilizing selective sentinel lymphadenectomy for patients with invasive breast carcinoma
31. Sentinel lymph node involvement - A predictor for axillary node status with breast cancer-has the time come?
32. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe
33. Impact of lymphoscintigraphy on sentinel node identification with technetium-99m-colloidal albumin in breast cancer
34. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes
35. Sentinel lymph node biopsy in breast cancer: Guidelines and pitfalls of lymphoscintigraphy and gamma probe detection
36. Ultrasonographically guided injection improves localization of the radiolabeled sentinel lymph node in breast cancer
37. Minimally invasive breast carcinoma staging using lymphatic mapping with radiolabeled dextran
38. Gamma-probe-guided resection of the sentinel lymph node in breast cancer
39. The sentinel node in breast cancer - A multicenter validation study
40. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer
41. Sentinel node biopsy in breast cancer
42. Sentinel lymph node biopsy in breast cancer: Initial experience at Memorial Sloan-Kettering Cancer Center
43. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer
44. Optimal histopathologic examination of the sentinel lymph node for breast carcinoma staging
45. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance
46. Prognostic significance of cytokeratin-positive breast cancer metastases
47. Prognostic importance of occult axillary lymph node micrometastases from breast cancer
48. Occult metastases in the axillary lymph nodes of patients with breast cancer node negative by clinical and histologic examination and conventional histology
49. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Re-evaluation with longer follow-up
50. Detection and significance of occult metastases in node-negative breast cancer
51. Prognostic significance of occult lymph node metastases in node-negative breast cancer
52. The significance of occult metastases: A study of breast cancer
53. Detection and significance of occult axillary node metastases in patients with invasive breast cancer
54. Axillary micro- and macrometastases in breast cancer: Prognostic significance of tumor size
55. Occult axillary lymph node metastases in invasive breast carcinoma: Characteristics of the primary tumor and significance of the metastases
56. Real-time ultrasound, axillary mammography, and clinical examination in the detection of axillary lymph node metastases in breast cancer patients
57. Clinical evaluation of axillary lymph nodes compared to surgical and pathological findings
58. Further analysis of predictive value of helix pomatia lectin binding to primary breast cancer for axillary and internal mammary lymph node metastases
59. The National Cancer Data Base report on breast cancer
60. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?
61. Factors affecting the incidence of lymph node metastases in small cancers of the breast
62. Axillary node status in nonpalpable breast cancer
63. Therapeutic effect of sentinel lymphadenectomy in T1 breast cancer
64. Prognosis based on primary breast carcinoma instead of pathological nodal status
65. Audit of complete axillary dissection in early breast cancer
66. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
67. Does sentinel lymphadenectomy improve staging and alter therapy in elderly women with breast cancer?
68. Sentinel lymph node technique for staging of breast cancer